Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial

Medicine and Dentistry

• Anthracycline 100%
• Cell Therapy 100%
• Congestive Heart Failure 100%
• Mesenchymal Stem Cell 100%
• Myocardial Disease 100%
• Cardiac Magnetic Resonance Imaging 66%
• Malignant Neoplasm 33%
• Quality of Life 16%
• Stem Cell 16%
• Biological Marker 16%
• Heart Function 16%
• Human Study 16%
• Functional Status 16%
• Six Minute Walk Test 16%
• Tumor 16%
• Cardiac Structure 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Congestive Heart Failure 100%
• Anthracycline 100%
• Myocardial Disease 100%
• Malignant Neoplasm 33%
• Human Study 16%
• Biological Marker 16%
• Functional Status 16%